EYETECH PHARMACEUTICALS INC 4
4 · EYETECH PHARMACEUTICALS INC · Filed Jan 5, 2005
Insider Transaction Report
Form 4
ADAMIS ANTHONY P
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2005-01-03$1.36/sh+8,212$11,168→ 27,536 total - Exercise/Conversion
Common Stock
2005-01-04$1.36/sh+8,212$11,168→ 27,536 total - Sale
Common Stock
2005-01-04$43.45/sh−8,212$356,811→ 19,324 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2005-01-04−8,212→ 57,105 totalExercise: $1.36From: 2002-07-01Exp: 2012-07-01→ Common Stock (8,212 underlying) - Exercise/Conversion
Incentive Stock Option (right to buy)
2005-01-03−8,212→ 65,317 totalExercise: $1.36From: 2002-07-01Exp: 2012-07-01→ Common Stock (8,212 underlying) - Sale
Common Stock
2005-01-03$45.21/sh−8,212$371,265→ 19,324 total
Holdings
- 6,280(indirect: by Daughter)
Common Stock
Footnotes (3)
- [F1]Transaction effected pursuant to a 10b5-1 plan dated July 7, 2004.
- [F2]These shares are held in a trust for the benefit of the reporting person's daughter. The reporting person's brother-in law is the trustee of the trust. The reporting person disclaims benefical ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for puposes of Section 16 or for any other purpose.
- [F3]These shares are held in a trust for the benefit of the reporting person's son. The reporting person's brother -in-law is the trustee of the trust. The reporting person disclaims beneficial ownership of these securiites, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for Section 16 or for any other pupose.